As most compounds target specific cancer pathways, identification of pathways and their potential role as drivers for cancer growths in the individual tumor has become an attractive approach for prediction of drug response. Mutation analysis of cancer relevant genes has become the most widely used approach because DNA is a robust molecule and barely affected by preanalytical factors.
However, the predictive value of DNA mutation analysis is limited by the fact that it does not reflect complex interaction of gene function and related protein interaction. Comprehensive analysis of target expression and key proteins of cancer pathways as well as their modifications (e.g., phosphorylation) can provide a much more detailed (and more predictive) picture of the individual tumor biology.
For reliable analysis and quantification of protein expression and Tissue Phenomics®, it needs tissues that have been collected under highly standardized conditions as studies from Indivumed have demonstrated. Therefore, Indivumed has established within the past 14 years a unique global clinical infrastructure with leading cancer clinics addressing these scientific challenges for preclinical research, clinical trials and subsequently patient care using precision medicine.
Prof. Dr. med. Hartmut Juhl, Founder and CEO, Indivumed GmbH and IndivuTest GmbH (Hamburg)
Hartmut Juhl attended the Medical School at Hamburg University, Germany and worked for 12 years as an academic surgeon in oncology and cancer research at the University Clinic Hamburg-Eppendorf and, later, Christian-Albrechts University in Kiel, Germany. In 1998 he became Associate Professor for Oncology and Surgery at Georgetown University, Washington, DC (USA).
In 2002, he founded Indivumed GmbH in Hamburg, as one of the first oncology research companies focused on precision medicine. Indivumed has cultivated a highly collaborative global clinical research infrastructure to secure and preserve biospecimens and data in a highly standardized manner which allows a comprehensive phenomic understanding of the indivudual’s cancer.
Hartmut Juhl is CEO of the Indivumed Group including IndivuTest GmbH, a clinical diagnostic laboratory founded in 2011, offering patients innovative diagnostic for individualizing cancer therapy. Hartmut Juhl holds an extraordinary professorship at the Medical Faculty of Hamburg University and is Adjunct Professor at the Lombardi Cancer Center of Georgetown University in Washington, D.C.
Who Should Attend?
This webinar will be ideal for Medical, Pharmaceutical, Biotech and Diagnostics executives, VPs and Directors of therapeutic areas, and Chief Scientific, Medical and Executive Officers.
It will also be informative for lab and study directors, and medical directors.
We improve patient lives by unlocking the tissue phenome.
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: http://www.definiens.com/.